The Pharmacokinetics of tadalafil in pregnant women and newborn infants
Not Applicable
- Conditions
- Pregnant women
- Registration Number
- JPRN-UMIN000028769
- Lead Sponsor
- Mie university hospital, Department of Obstetrics and Gynecology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Attending physician decides to entry inappropriate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The time course of serum concentration of tadalafil
- Secondary Outcome Measures
Name Time Method 1. The effect of pregnancy on serum concentration of tadalafil. 2. The effect of pregnancy on urine concentration of cGMP. 3. The effect of complications during pregnancy (FGR and PIH) on serum concentration of tadalafil. 4. The effect of complications during pregnancy (FGR and PIH) on urine concentration of cGMP. 5. The effect of pregnancy on blood pressure after administration of tadalafil. 6. The effect of complications during pregnancy (FGR and PIH) on blood pressure after administration of tadalafil. 7. The time course of serum concentration of tadalafil in newborn infants. 8. The effect of twin pregnancy on the outcomes above (No.1-7).